User login
The Multiple Myeloma Research Foundation (MMRF) has achieved its goal of acquiring participation from 1,000 multiple myeloma patients in its CoMMpass study, the foundation said in a statement.
Each participant in the MMRF CoMMpass Studyprovides bone marrow samples at diagnosis and when condition changes occur over the course of at least 8 years. The study opened in July of 2011 and involves the mapping of the genomic profiles of its participants, who are from more than 100 sites in the United States, Canada, and the European Union.
The study “will provide one of the most comprehensive clinical-genomic maps of any cancer. Beyond identifying novel biomarkers and therapeutic targets, the results will help physicians make informed and customized treatment decisions for their patients through data that show which individual and combined therapies work based on a specific profile, and will also help us identify mutations. This deep understanding ultimately leads to better, more precises care, as well as the promise of a cure,” said principal investigator Dr. Sagar Lonial, professor and executive vice chair in the department of hematology and medical oncology and chief medical officer at Winship Cancer Institute, Emory University, Atlanta.
Outputs from the study are accessible through the MMRF Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data available for additional study. Read more about the study on the foundation’s website.
The Multiple Myeloma Research Foundation (MMRF) has achieved its goal of acquiring participation from 1,000 multiple myeloma patients in its CoMMpass study, the foundation said in a statement.
Each participant in the MMRF CoMMpass Studyprovides bone marrow samples at diagnosis and when condition changes occur over the course of at least 8 years. The study opened in July of 2011 and involves the mapping of the genomic profiles of its participants, who are from more than 100 sites in the United States, Canada, and the European Union.
The study “will provide one of the most comprehensive clinical-genomic maps of any cancer. Beyond identifying novel biomarkers and therapeutic targets, the results will help physicians make informed and customized treatment decisions for their patients through data that show which individual and combined therapies work based on a specific profile, and will also help us identify mutations. This deep understanding ultimately leads to better, more precises care, as well as the promise of a cure,” said principal investigator Dr. Sagar Lonial, professor and executive vice chair in the department of hematology and medical oncology and chief medical officer at Winship Cancer Institute, Emory University, Atlanta.
Outputs from the study are accessible through the MMRF Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data available for additional study. Read more about the study on the foundation’s website.
The Multiple Myeloma Research Foundation (MMRF) has achieved its goal of acquiring participation from 1,000 multiple myeloma patients in its CoMMpass study, the foundation said in a statement.
Each participant in the MMRF CoMMpass Studyprovides bone marrow samples at diagnosis and when condition changes occur over the course of at least 8 years. The study opened in July of 2011 and involves the mapping of the genomic profiles of its participants, who are from more than 100 sites in the United States, Canada, and the European Union.
The study “will provide one of the most comprehensive clinical-genomic maps of any cancer. Beyond identifying novel biomarkers and therapeutic targets, the results will help physicians make informed and customized treatment decisions for their patients through data that show which individual and combined therapies work based on a specific profile, and will also help us identify mutations. This deep understanding ultimately leads to better, more precises care, as well as the promise of a cure,” said principal investigator Dr. Sagar Lonial, professor and executive vice chair in the department of hematology and medical oncology and chief medical officer at Winship Cancer Institute, Emory University, Atlanta.
Outputs from the study are accessible through the MMRF Researcher Gateway, an online, open-access portal designed to make key genomic and clinical data available for additional study. Read more about the study on the foundation’s website.